epsi-gam

epsi-gam (also known as T-101) is a recombinant bifunctional fusion protein developed by Tunitas Therapeutics for the treatment of allergic diseases. It consists of the Fc domains of human IgE and IgG1, designed to simultaneously bind and cross-link the high-affinity IgE receptor (FcεRI) and the inhibitory IgG receptor (FcγRIIb) on the surface of mast cells and basophils. This co-aggregation recruits the phosphatase SHIP to the FcεRI signaling complex, thereby inhibiting the release of histamine and other inflammatory mediators. This mechanism is allergen-agnostic, meaning it can potentially treat multiple allergies (such as cat, dust mite, and Bermuda grass) by silencing the effector cells regardless of the specific allergen trigger. Although it completed a Phase 1 dose-escalation study (NCT02230059), development appears to have ceased following the inactivity of Tunitas Therapeutics.

Other names

IgE-IgG fusion protein